Logo
Cincelar Plus + 5 x 8ml

Cincelar Plus + 5 x 8ml

Cincelar Plus

Aesthetic medicine injectable
  • Described by distributors as manufactured in medical equipment GMP Certified facilities in South Korea.
  • Listed by at least one trade source as EU – CPNP registered.
  • Marketing materials emphasise that the active component deoxycholic acid is a US FDA Approved fat Dissolving bile acid in certain injectable formulations, although this refers to the ingredient rather than this specific branded product.
  • LPG Clinics Wholesale notes that all of its products are CE or CPNP approved where appropriate.
Deoxycholic acid-based fat dissolving solution

Description

Cincelar Plus is an injectable, deoxycholic acid-based fat dissolving solution supplied as a box of 5 x 8 ml vials. It is designed for targeted reduction of localised subcutaneous fat on the face and body (such as double chin, abdomen, thighs and flanks) by destroying fat cells rather than shrinking them. The product is a gold translucent solution presented in sealed amber glass vials and is manufactured in Korean GMP facilities for use by trained medical and aesthetic professionals seeking non-surgical facial and body contouring.

Bnefits

  • Targets localised fat deposits on the face and body for contouring rather than general weight loss.
  • Uses deoxycholic acid to induce destruction of fat cells, providing long-lasting results with no yo-yo effect when combined with a healthy lifestyle.
  • Promotes natural and sharp facial and body lines by decreasing redundant lipids and adipocytes in the treatment area.
  • Described as painless or minimally uncomfortable and does not require lidocaine to be mixed with the solution.
  • Has few commonly reported side effects such as transient swelling, bruising or redness at the injection sites.
  • Triggers a mild inflammatory response (chemotaxis) that stimulates fibroblasts, promotes collagen production and can improve skin elasticity and firmness.
  • Non-surgical alternative to liposuction for suitable small to moderate fat pockets.
  • Manufactured in medical equipment GMP facilities and marketed as meeting EU CPNP registration requirements where applicable.

Indications

  • Injection lipolysis of localised, diet- and exercise-resistant subcutaneous fat deposits on the face or body (for example submental area/double chin, abdomen, flanks, thighs, upper arms, bra/back fat, knees and similar areas), in adults with normal weight or mild overweight.
  • Non-surgical facial and body contouring where reduction of small fat pockets is desired rather than overall weight loss.
  • Patients seeking definition of facial contours (such as jawline) and improvement of body silhouette with minimal downtime, under the care of a trained medical professional.

Composition

  • Active component: Deoxycholic acid (as sodium deoxycholate), a bile acid used for fat emulsification and lipolysis.
  • Water (aqua).
  • Glycerine / glycerin.
  • Sodium deoxycholate.
  • Sodium chloride.
  • Carnitine.
  • Vitamin B (commonly described as including Vitamin B2 / riboflavin).

Formulation

  • Gold translucent liquid solution.
  • Supplied in sealed amber glass vials.
  • Each vial contains 8 ml of solution.
  • Box presentation: 5 vials x 8 ml (total 40 ml per box).
  • Deoxycholic acid-based fat dissolving injectable for professional use only.

Packaging

  • Primary packaging: Amber glass vials containing 8 ml of Cincelar Plus solution, sealed for sterility.
  • Secondary packaging: Carton box containing 5 x 8 ml vials per box.
  • Labeling typically includes product name (Cincelar+ / Cincelar Plus), volume, ingredients, batch number, and expiry date.
  • Intended for professional aesthetic or medical clinic use; shipped and stored as a temperature-controlled injectable product.

Usage

  • For professional use only by suitably trained medical or aesthetic practitioners familiar with injectable lipolysis and local anatomy.
  • Attach an appropriate sterile needle to a sterile syringe and draw up the required volume of solution according to the treatment plan.
  • Inject small aliquots (typically 0.3–0.4 ml per injection point) into the subcutaneous fat layer of the selected treatment area, spacing injections approximately 1.0–2.0 cm apart.
  • Use closer spacing (around 1.0 cm) along the chin/jawline and wider spacing (around 2.0 cm) for larger body areas, following the manufacturer’s guidance and clinical judgment.
  • Do not exceed a total of 2 vials (16 ml) in a single treatment session according to published protocols; one-time dose is commonly described as 2 vials for larger treatment zones.
  • Maintain a minimum interval of around 4 weeks between treatments to the same anatomical area; other areas may be treated sooner according to protocol and professional judgment.
  • Maximum recommended use is up to 6 treatment sessions to the same area (approximate total treatment duration of 24 weeks), with many patients requiring 2–3 sessions for satisfactory results.
  • After treatment, provide patients with aftercare instructions such as avoiding high heat exposure (sauna, steam rooms, hot tubs), intensive massage, vigorous exercise, and alcohol for a specified period (commonly 48–72 hours for exercise and several days for heat or alcohol), and to follow any clinic-specific protocols.
  • Always follow local regulations, clinical guidelines, and the latest official instructions from the manufacturer or authorised distributors; adjust doses and treatment plans based on patient assessment, area size and response.

Contraindications

  • Pregnancy and breastfeeding.
  • Known hypersensitivity or intolerance to deoxycholic acid (sodium deoxycholate) or any component of the formulation (e.g. glycerin/glycerine, sodium chloride, carnitine, vitamin B).
  • Significant liver or kidney disease.
  • Blood clotting disorders or use of certain anticoagulant/antiplatelet medications where injection-related bleeding risk is increased, unless carefully assessed and approved by the treating clinician.
  • Acute systemic illness such as active infection, fever, flu or severe inflammatory conditions at the time of treatment.
  • Obesity (commonly defined in marketing material as BMI > 30), where the product is not intended as a weight-loss treatment.
  • Active skin infection, inflammation, open wounds or dermatologic disease at the intended injection sites.
  • Any other condition in which injectable lipolysis is contraindicated according to local clinical guidelines or the treating practitioner’s judgment.

Adverse Effects

  • Commonly reported local reactions at the injection site such as transient swelling, bruising and redness.
  • Temporary tenderness, mild discomfort or a sensation of fullness in the treated area as fat cells are disrupted and inflammatory processes occur.
  • Short-term inflammatory response (chemotaxis) in the treated tissue, associated with fibroblast stimulation and collagen production.
  • Possible temporary induration, nodularity or unevenness in the treated fat layer during the resorption phase.
  • As with any injectable treatment, there is a risk of bleeding, hematoma, infection, allergic reaction, nerve or vascular injury if the product is injected incorrectly or aseptic technique is not followed; these require prompt clinical evaluation.

Storage Conditions

  • Store at room temperature, typically within 5–25 °C as stated by LPG Clinics Wholesale, or within 1–30 °C as described by other distributors.
  • Keep away from direct sunlight and sources of heat (shaded storage).
  • Do not freeze.
  • Keep vials in their original packaging until use and observe the expiry date (2 years from date of manufacture as indicated by distributors).
  • Store out of reach of unauthorised personnel and in accordance with local regulations for injectable aesthetic products.

Duration

Typically performed as a series of 2\u20133 treatment sessions per area, with a maximum of 6 sessions to the same area at approximately 4-week intervals (total course up to around 24 weeks), depending on the size of the fat pocket, patient goals and clinical response.

Onset

Initial changes are generally reported from about 1\u20132 weeks after injection as inflammatory and lipolytic processes occur, with clearer visible fat reduction usually confirmed around 4 weeks post-treatment. Optimal contouring results may develop over several weeks and may require multiple sessions.

Browse more Aesthetic medicine injectable

Top Treatments

Top Cities in the UK